AKT1 and cancer: With an emphasis on HL60 and liver HepG2 cancer cell lines, the most active compounds were investigated for their inhibition of the PI3K/AKT pathway by gene and protein expression levels to prove and finally by the in-silico studies to confirm the mechanism of action.